AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|
23.7 C
New York
Thursday, July 23, 2026

Tag: nausea

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

TWL Announces Expanded Online Access to GLP-1 Weight-Loss Care With Insurance and Self-Pay Options

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients
Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients

AM Rx Announces Expanded Online Access and Insurance Support for Zepbound

Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care
Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

/C O R R E C T I O N — O Positiv Health/

In the news release, O Positiv Health Releases Its First Prenatal, PREGGO Prenatal + Probiotic, issued 10-Feb-2026 by O Positiv Health over PR Newswire,...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNausea